Description: Nextage Therapeutics Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. It offers CellDetect, a diagnostic platform for early cancer detection, including bladder cancer, cervical cancer, and prostate cancer. The company also provides BRONJ Test, a test for bisphosphonate-related osteonecrosis of the jaw. In addition, it offers gene expression, and biomarker and histochemical assays for early cancer detection and personalized medicine. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. The company was formerly known as Micromedic Technologies Ltd and changed its name to Nextage Therapeutics Ltd in August 2020. Nextage Therapeutics Ltd is based in Tel Aviv, Israel.
Home Page: www.m-medic.com
Officers
| Name | Title |
|---|---|
| Mr. Meir Yoeli | Chief Exec. Officer |
| Mr. Itai Bar-Natan | Chief Financial Officer |
| Dr. Yael A. Glickman | VP of Bus. Devel. |
Exchange: TA
Country: IL
Currency: Israeli Agora (ILA)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.6834 |
| Price-to-Sales TTM: | 26.1117 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |